Pharmaceutical Opportunities

An Expert's View about Human Health Services in France

Last updated: 21 Aug 2011

The French Biopharmaceutical market size (€50bn in 2009) and high per capita drug expenditure (€550 in 2009) makes France an attractive location in which to do business and set up operations.

Sector briefing Biotechnology & pharmaceutical opportunities in France Why France? The French Biopharmaceutical market size (?50bn in 2009) and high per capita drug expenditure (?550 in 2009) makes France an attractive location in which to do business and set up operations. According to the Leem and France Biotech (the French Pharmaceutical and Biotech Trade associations), - France is home to 324 pharmaceutical firms and 250 biotech firms in 2009; - Biopharma industry employs 105,000 people, including 22,000 involved in R&D and 20,000 in biotechnologies; - Sales have doubled in 10 years, with a 5% growth, though slightly reduced with the economic crisis; ?Ranking world?s number - 12.5% of sales revenue is dedicated to three in sales (?50bn), France R&D and ?5bn is invested annually in is also Europe?s number one research into new drugs. for drug manufacturing with Find general information on the French market 220 production sites?. conditions on UKTI?s website. The Doing Business Guide for France gives an overview of France?s economy, business culture, potential opportunities and an introduction to other relevant issues. UK Trade & Investment Sector briefing: Biotech & Pharma opportunities in France ? The French Government has pledged Opportunities ?21.9 billion to increase the international competitiveness and French key players attractiveness of Research and Higher Education. This funding will for example The number of biopharmaceutical companies benefit to Research Equipment of operating in France has increased over the past Excellence, biotech and bio-resources decade and the domestic industry is well projects, Technological Research developed with many companies focusing on Institutes (IRTs) (?2bn for 6 centres, of the development of novel drugs. which Lyon), SATT (Technology Transfer Agencies) (?1bn for 10 centres). Pharmaceutical 2010 Sales in ? laboratory billion Numerous opportunities arise from potential 1 Sanofi 30.4 new drivers of future growth, such as: 2 Servier 3.7 - New relationships, with increasing 3 Pierre Fabre 1.9 pharma partnering with Contract 4 BioMérieux 1.6 Research Organisations (CROs) and 5 Ipsen 1.2 Contract Manufacturing Organisations 6 LFB 0.41 (CMOs), and with biotech SMEs, alongside increased collaboration France also boasts world-class public and between industry and academia; private scientific research expertise (CNRS, - Increasing complexity of manufacturing INSERM, Institut Curie, Institut G. Roussy, for the production of bio- Inst. Pasteur, CEA, INRA, University Hospitals pharmaceuticals: France is catching up (AP-HP, HCL, AP-HM, CHU?) etc?. fast with 27 operating biomanufacturing sites, of which the Sanofi?s biolaunch Most life science companies are located in one site in Paris area; of three French regions: the Paris Ile de France - Growing convergence and changes in region (33%), the Rhône-Alpes region (16.6%) Information Technology, creating and the Provence-Alpes-Côte d?Azur (PACA) opportunities for novel approaches to region (10.5%). SMEs make up the majority of patient treatment and care: vast variety the industry, with an average of 25 employees. of opportunities in telemedicine and e- healthcare; Key government initiatives to support the - Emerging technologies arising from biopharma industry advances in biology, such as platform technologies, micro & nanotechnologies To increase France?s international and stratified/personalised medicine. attractiveness and competitiveness, the sector has in recent years benefitted from New sources of revenue growth: government policies which encourage the ? High value products e.g. biologics private sector to invest in research, to develop (fast growing segment and expected technology transfer and synergies between to represent 15% of all marketed academia and industry, and to support SME drugs by 2012), advanced and growth. France?s flagship innovation initiatives targeted therapies (particularly in are: oncology area), stratified and - the competitiveness clusters: speciality medicines, orphan disease The drugs and areas of unmet medical main competitive clusters which have been need. classified as world-class, or aspiring to be are: ? Diversification away from reliance on Medicen Paris region (Greater Paris area), novel drugs into less risky areas LyonBiopole (Lyon-Grenoble region), Alsace such as: Biovalley (Strasbourg area) and Atlantic o generics and biosimilars: they Biothérapies (Nantes-Angers area); are still growing and now represent 25% of the biopharma - the R&D tax credit (Crédit d?Impôt market in volume and 14% in Recherche- CIR); value; o non-pharmaceutical - The Future Investments Programme (so- products/OTCs called ?Grand Emprunt?): UK Trade & Investment Sector briefing: Biotech & Pharma opportunities in France o personal care/cosmetics: France is a world leader in this sub- sector with sales of ?18bn and key players such as L?Oreal and Pierre Fabre. ? Vaccines: therapeutic and novel vaccines, higher cost vaccines: Sanofi Pasteur is a world leader, ? Animal health products (Merial is a world leader), ? Diagnostics/theranostics (early health, biomarkers, stratified medicine) with BioMérieux as world leader. ? The « Grey-gold market » : ageing population stimulating demand for chronic treatments (by 2030, 28% of pop > 65 years old). Last but not least, the French Ministry of Industry recently published a complete list of its key technologies (KTs) for France 2015- 2020: 85 KTs in total, across 7 sectors, of which ?Health, agriculture, food? with 10 KTs: cell and tissue engineering, genomic engineering, immune system engineering, synthetic biology, bio-embedded systems, real-time monitoring, microbial ecosystem management, rapid diagnostics, medical imaging, sanitation). If you have any questions on the opportunities above, contact the UKTI contacts named in this report. Business opportunities aimed specifically at UK companies are added daily to UKTI?s website. These leads are sourced by our staff overseas in British Embassies, High Commissions and Consulates, across all sectors and in over 100 markets. You can be alerted to business opportunities on a regular basis by registering on the UKTI website. Find out more on UKTI?s business opportunities service on the UKTI website. UK Trade & Investment Sector briefing: Biotech & Pharma opportunities in France Major events and activities UKTI contacts POLEPHARMA MEETINGS Laurent Faye Senior Biotech & Pharma Trade Adviser Time: 21-22 September 2011 British Consulate Lyon French business convention held in Dreux Tel: (00 33) 4 72 77 83 21 Email: WORLD VACCINE CONGRESS congress-lyon/ Anne-Marie Coffy Time: 10-13 October 2011 Deputy Biotech & Pharma Trade Adviser International Conference on the vaccine British Consulate Lyon market and related issues held in Lyon Tel: (00 33) 4 72 77 83 25 Email: PCH MEETINGS Time: 27-28 March 2012 French business convention held in Lyon Key trade associations LEEM (LEs Entreprises du Médicament) 88 rue de la Faisanderie 75016 PARIS Tel: +33 (0)1 45 03 88 88 Internet: Main French pharmaceutical trade association. FRANCE BIOTECH Hôpital Saint Louis 1 avenue Claude Vellefaux 75010 PARIS Tel: +33 (0) 1 56 58 10 70 Email: Internet: Main French biotechnology trade association. Find full details of all events in this country and sector on the UKTI website. New export events are added daily to the site and you can register to be alerted to them on a daily, weekly or monthly basis UKTI?s Tradeshow Access Programme (TAP) provides grant support for eligible Small & Medium Sized Enterprises (SME's) to attend trade shows overseas. Find out more about UKTI support for attendance at overseas events. UK Trade & Investment Sector briefing: Biotech & Pharma opportunities in France Next steps - How UKTI can help ? Arranging appointments British companies wishing to develop their ? Organise seminars or other events for business in the French market are advised to you to meet contacts and promote your undertake as much market research and company in the French market planning as possible in the UK. UKTI?s team in France, with its wide local knowledge and This work is available via our Overseas Market experience, can provide a range of services to Introduction Service (OMIS) a chargeable British-based companies wishing to grow their service which assists British-based companies business in global markets. wishing to enter or expand their business in overseas markets. This can include: ? Provision of market information To find out more about commissioning this ? Validated lists of work, or accessing other UKTI services and agents/distributors/partners specialist advice, please visit the UKTI website ? Key market players or potential to find contact details for your local UKTI customers in the French market office. ? Establishment of interest of such contacts in working with you Whereas every effort has been made to ensure that the information given in this document is accurate, neither UK Trade & Investment nor its parent Departments (the Department for Business, Innovation & Skills, and the Foreign & Commonwealth Office), accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. Published 2011 by UK Trade & Investment. Crown Copyright © You may reuse this information (not including logos, images and case studies) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit licence/ or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: This publication is also available from our website at or for more information please telephone +44 (0)20 7215 8000. UK Trade & Investment Sector briefing: Biotech & Pharma opportunities in France
Posted: 21 August 2011, last updated 21 August 2011

See more from Human Health Services in France

Expert Views    
Pharmaceutical Opportunities   By UK Trade & Investment
HealthCare opportunities   By UK Trade & Investment
CE Marking of In Vitro Diagnostic Medical Devices   By U.S. Commercial Service